Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

The end of the beginning for genomic medicine

Nature Biotechnology volume 19, pages 207–209 (2001)Cite this article

The human genome sequence yields several surprises for researchers seeking to exploit genomic data in drug discovery

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Genomic information-driven drug discovery.

© Bob Crimi

References

  1. International Human Genome Sequencing Consortium. Nature 409, 860–921 (2001).

  2. Data from S.G. Cowen (2001).

  3. Liang, F. et al. Nat. Genet. 25, 239–240 (2000).

    Article  CAS  Google Scholar 

  4. Roizman, B. Nature 288, 2327–2328 (2000).

    CAS  Google Scholar 

  5. Paarmann, I., Frermann, D., Keller, B.B.B.U. & Hollmann, M. J. Neurochem. 74, 1335–1345 (2000).

    Article  CAS  Google Scholar 

  6. Pandey, A. & Mann, M. Nature 405, 837–846 (2000).

    Article  CAS  Google Scholar 

  7. Olszewski, K.A., Yan, L., Edwards, D. & Yeh, T. Comput. Chem. 24, 499–510 (2000).

    Article  CAS  Google Scholar 

  8. Roses, A.D. Nature 405, 857–865 (2000).

    Article  CAS  Google Scholar 

  9. Drews, J. Science 287, 1960–1964 (2000).

    Article  CAS  Google Scholar 

  10. Service, R.F. Science 287, 1954–1956 (2000).

    Article  CAS  Google Scholar 

  11. Hofmann, K., Bucher, P., Falquet, L. & Bairoch, A. Nucleic Acids Res. 27, 215–219 (1999).

    Article  CAS  Google Scholar 

  12. Leach, A.R., Bryce, R.A. & Robinson, A.J. J. Mol. Graph. Model. 18, 358–367 (2000).

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. David Bailey, Edward Zanders and Philip Dean: David Bailey is chief executive officer, Edward Zanders is vice president discovery genomics, Philip Dean is chief scientific officer

Authors and Affiliations

  1. De Novo Pharmaceuticals, 59 St Andrews Street, Cambridge, CB2 3DD, UK

    David Bailey, Edward Zanders & Philip Dean

Authors
  1. David Bailey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward Zanders
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip Dean
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bailey, D., Zanders, E. & Dean, P. The end of the beginning for genomic medicine. Nat Biotechnol 19, 207–209 (2001). https://doi.org/10.1038/85627

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/85627

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing